Announcements
- Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
- Assembly Biosciences Announces Effective Date of Reverse Stock Split
- Assembly Biosciences Provides Anticipated Development Milestones for 2024
- Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®
- Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates
- Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
- Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
- Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
More ▼
Key statistics
As of last trade Assembly Biosciences Inc (V7B:STU) traded at 13.40, -7.25% below its 52-week high of 14.45, set on Apr 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.00 |
---|---|
High | 13.40 |
Low | 13.00 |
Bid | 13.20 |
Offer | 14.00 |
Previous close | 13.10 |
Average volume | 0.00 |
---|---|
Shares outstanding | 5.51m |
Free float | 3.69m |
P/E (TTM) | -- |
Market cap | 82.48m USD |
EPS (TTM) | -11.22 USD |
Data delayed at least 15 minutes, as of May 20 2024.
More ▼